ScreenerHero

COGTCogent Biosciences, Inc.

NAS · US · Healthcare · Biotechnology · cogentbio.com
36.73USD-0.33%Mkt Cap: 6.37B $P/E: —

Cogent Biosciences, Inc., a clinical-stage biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyros…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0
HeadlineSourceTime
Older
Biotech ETF (CANC) Hits New 52-Week High

CANC hits a 52-week high as strong oncology developments and positive momentum fuel the biotech ETF's rally.

Zacks
Cogent Biosciences (COGT) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

Cogent Biosciences (COGT) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

Zacks
Cogent Bioscience (COGT) Files New Drug Application For Bezuclastinib

Cogent Biosciences Inc. (NASDAQ:COGT) is one of the 10 affordable biotech stocks to buy right now. On June 30, Cogent Bioscience Inc. (NASDAQ:COGT) disclosed that it filed a New Drug Application for bezuclastinib, a drug for the treatment of Advanced Systemic Mastocytosis. The application to the U.S. FDA is backed by encouraging clinical results from […]

IInsider Monkey
Is Cogent Biosciences (COGT) ’s New Cancer Drug 100 Times More Precise Than What’s Already on the Market?
IInsider Monkey
Cogent Biosciences' Potential Rare Blood Disease Treatment Meets Endpoints in Clinical Trial
MMT Newswires
How Investors May Respond To Cogent Biosciences (COGT) Priority Review For Bezuclastinib GIST Regimen
Simply Wall St.
Is Cogent Biosciences, Inc. (COGT) A Good Stock To Buy Now?
IInsider Monkey
This $5.5 Million Exit Raises Questions After Wave Life Sciences' Rough First Quarter
Motley Fool
Assessing Cogent Biosciences (COGT) Valuation After A Strong Year And Recent Share Price Pullback
Simply Wall St.